fbpx
  • Panels
    • ePlex Panels
      • Respiratory
      • Blood Culture
    • XT-8 Panels
  • Systems
    • ePlex System
      • Software Solutions
      • Patient Safety
    • XT-8 System
  • Company
    • The GenMark Story
    • Careers
      • Opportunities
    • Newsroom
  • Education
    • Disease State
      • Sepsis
      • Respiratory Infections
      • Hepatitis C
      • GI Infections
    • Technology
    • Resources
  • Support
    • Contact Us
    • FAQs
    • Safety Data Sheets (SDS)
    • Your Long-Term Partner
  • Customer Resource Center
Select your region:
  • United States
SELECT YOUR REGION:
  • United States
| CONTACT US | CUSTOMER RESOURCE CENTER
GenMark
  • Panels
    • ePlex Panels
      • Respiratory
      • Blood Culture
    • XT-8 Panels
  • Systems
    • ePlex System
      • Software Solutions
      • Patient Safety
    • XT-8 System
  • Company
    • The GenMark Story
    • Careers
      • Opportunities
    • Newsroom
  • Education
    • Disease State
      • Sepsis
      • Respiratory Infections
      • Hepatitis C
      • GI Infections
    • Technology
    • Resources
  • Support
    • Contact Us
    • FAQs
    • Safety Data Sheets (SDS)
    • Your Long-Term Partner
  • Customer Resource Center

Detection of Omicron variant on the ePlex® RP2 Panel*

November 29, 2021

A new SARS-CoV-2 variant first reported in South Africa and Botswana, B.1.1.529, has now been designated by the WHO as a Variant of Concern (VOC) and assigned the Greek name Omicron.1 In the US, this variant is being closely monitored though no cases have been reported yet. Globally, cases have been reported in Australia, Britain, Belgium, Botswana, Denmark, Germany, France, Italy, Hong Kong, Israel, Netherlands, Czech Republic, Austria, Canada, and South Africa; this list is quickly expanding as additional cases are identified.2 The number of mutations in this variant is causing concern, and over 30 mutations have been reported in the spike protein region alone.3 A virologist in the UK noted this is the most heavily mutated version of the virus yet identified.4

 

The GenMark ePlex Respiratory Pathogen Panel 2 (RP2 Panel) targets 2 unique regions of the N gene. Preliminary analysis of the Omicron variant based on 91 sequences available in GISAID (as of November 26, 2021) indicates that there are no detrimental mutations in the N gene regions targeted by the ePlex RP2 Panel SARS-CoV-2 assays and there is predicted inclusivity of 100% for this variant.

 

Click here to learn more about other SARS-CoV-2 variant detection on the ePlex RP2 Panel.

*The ePlex RP2 Panel is for use under Emergency Use Authorization (EUA) only. This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2 and multiple respiratory viral and bacterial organisms; and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

 


1. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
2. https://www.washingtonpost.com/health/2021/11/26/faq-new-variant-omicron/#4DY5HIILCFB4ROXR3NLC4OKKKI
3. https://www.nytimes.com/live/2021/11/28/world/covid-omicron-variant-news
4. https://www.cnn.com/2021/11/26/africa/new-covid-variant-discovered-south-africa-b11529-intl/index.html

GenMark Diagnostics, Inc.
5964 La Place Court
Carlsbad, CA 92008

 

© Copyright 2022 GenMark Diagnostics, Inc.
All rights reserved.

 

 
 
 
 

Legal | Privacy Policy

 

 

This website uses cookies to improve your experience. Read More. You can opt-out if you wish. Change settingsACCEPT REJECT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
Popup Button